What this study is
The purpose of this research is to evaluate novel technologies for the assessment of ocular structure and function, including the scanning device called Optical Coherence Tomography (OCT). We will test the OCT and other devices in their ability to image diseases of the eye and also compare the measurements made with OCT to those of other imaging and visual field devices approved by the Food and Drug Administration (FDA). OCT may be useful for the early diagnosis and monitoring of a variety of types of eye diseases
Study details
- Official title
- Novel Diagnostics for Ocular Structure
- Sponsor
- Wills Eye
- Conditions
- Glaucoma · Macular Disease
- Enrolling
- 5,000 people
- Starts
- 2000-08-01
- Est. completion
- 2029-07-31
- Record
- View on ClinicalTrials.gov ↗
Who can join
Age 18 Years and overSex ALLHealthy volunteers AcceptedYou may qualify if
- Ability to provide informed consent and to understand the study procedures
- Healthy volunteers
- Age related macular degeneration (AMD), diabetic retinopathy, central serous chorioretinopathy, and/or glaucoma or glaucoma suspects
- (AD Sub-Study ONLY): Subjects diagnosed with AD or MCI.
You can't join if
- Any medical treatment (e.g., chronic corticosteroid, hydroxychloroquine, chloroquine, thioridazine, canthaxanthine) or conditions that affect VF (e.g., stroke) and retinal thickness other than glaucoma.
- Strabismus, nystagmus, or any condition that prevents fixation.
- Presence of any media opacities that hinders clinical view of the fundus, and any intraocular non-glaucomatous abnormality
- History of ocular trauma or intraocular surgery other than uncomplicated glaucoma interventions or cataract extraction at least 3 months previous to participating in the study.
Sign in and we'll check these against your records.Full criteria on ClinicalTrials.gov ↗
Loading treatment details…
Study locations (1)
1 openWills Eye Hospital
Philadelphia, Pennsylvania, United States
- Taylor Harwood · Contact215-928-3197tharwood@willseye.org
- Ronald Zambrano · Contact215-928-3197rzambrano@willseye.org
- Joel S Schuman, MD · Principal investigator
- Gadi Wollstein, MD · Sub-investigator
Recruiting
Study team
Sponsor
Wills Eye
Study ID 2023-37 - R01EY013178
Study chair
Joel S Schumann, MD
Wills Eye Hospital
Frequently asked questions
The sponsor hasn't published answers to common questions for this trial.